Developments toward the Implementation of 44Sc Production at a Medical Cyclotron.
- van der Meulen NP Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.
- Hasler R Center of Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.
- Talip Z Center of Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.
- Grundler PV Center of Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.
- Favaretto C Center of Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.
- Umbricht CA Center of Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.
- Müller C Center of Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland.
- Dellepiane G Albert Einstein Center for Fundamental Physics, Laboratory of High Energy Physics, University of Bern, 3012 Bern, Switzerland.
- Carzaniga TS Albert Einstein Center for Fundamental Physics, Laboratory of High Energy Physics, University of Bern, 3012 Bern, Switzerland.
- Braccini S Albert Einstein Center for Fundamental Physics, Laboratory of High Energy Physics, University of Bern, 3012 Bern, Switzerland.
- 2020-10-17
Published in:
- Molecules (Basel, Switzerland). - 2020
English
44Sc has favorable properties for cancer diagnosis using Positron Emission Tomography (PET) making it a promising candidate for application in nuclear medicine. The implementation of its production with existing compact medical cyclotrons would mean the next essential milestone in the development of this radionuclide. While the production and application of 44Sc has been comprehensively investigated, the development of specific targetry and irradiation methods is of paramount importance. As a result, the target was optimized for the 44Ca(p,n)44Sc nuclear reaction using CaO instead of CaCO3, ensuring decrease in target radioactive degassing during irradiation and increased radionuclidic yield. Irradiations were performed at the research cyclotron at the Paul Scherrer Institute (~11 MeV, 50 µA, 90 min) and the medical cyclotron at the University of Bern (~13 MeV, 10 µA, 240 min), with yields varying from 200 MBq to 16 GBq. The development of targetry, chemical separation as well as the practical issues and implications of irradiations, are analyzed and discussed. As a proof-of-concept study, the 44Sc produced at the medical cyclotron was used for a preclinical study using a previously developed albumin-binding prostate-specific membrane antigen (PSMA) ligand. This work demonstrates the feasibility to produce 44Sc with high yields and radionuclidic purity using a medical cyclotron, equipped with a commercial solid target station.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.3390/molecules25204706
- PMID 33066650
- Persistent URL
- https://folia.unifr.ch/global/documents/233679
Statistics
Document views: 17
File downloads:
- fulltext.pdf: 0